Works Cited

1. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance—United States, 2016. Available at https://www.cdc.gov/hepatitis/statistics/2016surveillance/index.htm. Last accessed February 6, 2019.

2. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction—eight states, 1998–2005. MMWR. 2008;57(6):144-148.

3. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294(16):2043-2051.

4. Centers for Disease Control and Prevention. Vaccination coverage among children aged 19–35 months—United States, 2017. MMWR. 2018;67(40):1123-1128.

5. Zhao Z, Smith PJ. Trends in vaccination coverage disparities among children, United States, 2001–2010. Vaccine. 2013;31(19):2324-2327.

6. Centers for Disease Control and Prevention. Measles Cases and Outbreaks. Available at https://www.cdc.gov/measles/cases-outbreaks.html. Last accessed February 6, 2019.

7. Centers for Disease Control and Prevention. Vaccination Coverage Among Adults in the United States, National Health Interview Survey, 2016. Available at https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/ NHIS-2016.html. Last accessed February 6, 2019.

8. Schaffner W. Update on vaccine-preventable diseases: are adults in your community adequately protected? J Fam Pract. 2008;57(4 suppl):S1-S11.

9. Centers for Disease Control and Prevention. Surveillance of vaccination coverage among adult populations—United States, 2015. MMWR. 2017;66(11):1-28.

10. Hall CB. The recommended childhood immunization schedule of the United States. Pediatrics. 1995;95(1):135-137.

11. Centers for Disease Control and Prevention. Past Immunization Schedules. Available at https://www.cdc.gov/vaccines/schedules/resource-library/index.html. Last accessed February 6, 2019.

12. Advisory Committee on Immunization Practices. Recommended immunization schedule for children and adolescents aged 18 years of younger—United States, 2019. MMWR. 2019;68(5):112-114.

13. Centers for Disease Control and Prevention. Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine. MMWR. 2009;58(36):1008-1009.

14. Centers for Disease Control and Prevention. Updated recommendations of the Advisory Committee on Immunization Practice (ACIP) regarding routine poliovirus administration. MMWR. 2009;58(30);829-830.

15. Centers for Disease Control and Prevention. Notice to readers: recommended adult immunization schedule—United States, 2002–2003. MMWR. 2002;51(40):904-908.

16. Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in human papillomavirus-associated cancers—United States, 1999–2015. MMWR. 2018;67(33);918-924.

17. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137(3):e1-e9.

18. Advisory Committee on Immunization Practices. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(41):1171-1176.

19. Advisory Committee on Immunization Practices. Recommended immunization schedule for adults aged 19 years or older— United States, 2019. MMWR. 2019;68(5):115-118.

20. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2019–20 influenza season. MMWR. 2019;68(3):1-21.

21. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR. 2008;57(RR7):1-60.

22. U.S. Food and Drug Administration. Highlights of Prescribing Information: FluMist Influenza Vaccine Live, Intranasal. Available at https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM294307.pdf. Last accessed February 7, 2018.

23. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006;55(RR3):1-34.

24. Centers for Disease Control and Prevention. 2017 Final Pertussis Surveillance Report. Available at https://www.cdc.gov/pertussis/downloads/pertuss-surv-report-2017.pdf. Last accessed February 6, 2019.

25. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006;55(RR17):1-33.

26. Centers for Disease Control and Prevention. Pneumococcal Disease Surveillance and Reporting. Available at https://www.cdc.gov/pneumococcal/surveillance.html. Last accessed February 7, 2019.

27. Government of the District of Columbia. District of Columbia Immunization Requirements School Year 2015–2016. Available at https://doh.dc.gov/sites/default/files/dc/sites/doh/Immunization%20Requirements-2.pdf. Last accessed February 7, 2019.

28. American Cancer Society. Key Statistics for Cervical Cancer. Available at https://www.cancer.org/cancer/cervical-cancer/about/ key-statistics.html. Last accessed February 6, 2019.

29. Centers for Disease Control and Prevention. Vaccines and Preventable Diseases: Who Should NOT Get Vaccinated with These Vaccines? Available at https://www.cdc.gov/vaccines/vpd/should-not-vacc.html. Last accessed February 7, 2019.

30. U.S. Food and Drug Administration. Vaccines, Blood and Biologics: Cervarix. Available at https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186957.htm. Last accessed February 7, 2019.

31. U.S. Food and Drug Administration. Vaccines, Blood and Biologics: Gardasil. Available at https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094042.htm. Last accessed February 7, 2019.

32. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2014;63(RR5):1-30.

33. Manhart LE, Holmes KK, Koutsky LA, et al. Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis. 2006;33(8):502-508.

34. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the U.S. JAMA. 2007;297(8):813-819.

35. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naïve women aged 16–26 years. J Infect Dis. 2009;199(7):926-935.

36. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301-314.

37. Merck. Highlights of Prescribing Information: Gardasil. Available at https://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf. Last accessed February 7, 2019.

38. Yih WK, Lieu TA, Kulldorff M, et al. Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med. 2014;370(6):503-512.

39. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11-22.

40. Cortese MM, Parashar UD. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2009;58(RR2):1-25.

41. Centers for Disease Control and Prevention. Rotavirus. Available at https://www.cdc.gov/rotavirus/index.html. Last accessed February 6, 2019.

42. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. MMWR. 2005;54(RR7):1-21.

43. Centers for Disease Control and Prevention. Meningococcal Disease: Technical and Clinical Information. Available at https://www.cdc.gov/meningococcal/clinical-info.html. Last accessed February 6, 2019.

44. Fishbein DB, Broder KR, Markowitz L, Messonnier N. New, and some not-so-new, vaccines for adolescents and diseases they prevent. Pediatrics. 2008;121(suppl 1):S5-S14.

45. Centers for Disease Control and Prevention. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use—Advisory Committee on Immunization Practices, 2010. MMWR. 2010;59(09);273.

46. U.S. Food and Drug Administration. First Vaccine Approved by FDA to Prevent Serogroup B Meningococcal Disease. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm420998.htm. Last accessed February 7, 2019.

47. Centers for Disease Control and Prevention. Notice to readers: revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11–18 years with meningococcal conjugate vaccine. MMWR. 2007;56(31):794-795.

48. Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006;55(RR7):1-23.

49. Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR. 2018;67(3):103-108.

50. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland M, Sy LS. A population-based study of the incidence and complications of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341-1349.

51. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284.

52. Centers for Disease Control and Prevention. Manual for the Surveillance of Vaccine-Preventable Diseases. 5th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2012.

53. Centers for Disease Control and Prevention. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine—United States, 1997–2006. MMWR. 2009;58(1):1-4.

54. Centers for Disease Control and Prevention. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR. 2012;61(21):394-395.

55. Centers for Disease Control and Prevention. Chart of Contraindications and Precautions to Commonly Used Vaccines. Available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html. Last accessed February 7, 2019.

56. Curran D, Oostvogels L, Heineman T, et al. Quality of life impact of a recombinant zoster vaccine in adults ≥50 years of age. J Gerontol A Biol Sci Med Sci. 2018; [Epub ahead of print].

57. Merck. Varivax (Varicella Virus Vaccine Live). Available at https://www.merck.com/product/usa/pi_circulars/v/varivax/varivax_pi.pdf. Last accessed February 7, 2019.

58. Merck. Highlights of Prescribing Information: Zostavax (Zoster Vaccine Live). Available at https://www.merck.com/product/ usa/pi_circulars/z/zostavax/zostavax_pi2.pdf. Last accessed February 7, 2019.

59. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007;56(RR4):1-40.

60. Merck. MMR-II (Measles, Mumps, and Rubella Virus Vaccine Live). Available at https://www.merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf. Last accessed February 7, 2018.

61. Merck. Highlights of Prescribing Information: RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent). Available at https://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_pi.pdf. Last accessed February 7, 2019.

62. GlaxoSmithKline. Highlights of Prescribing Information: Rotarix (Rotavirus Vaccine, Live, Oral). Available at https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Rotarix/pdf/ROTARIX-PI-PIL.PDF. Last accessed February 7, 2019.

63. Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Update on recommendations for use of herpes zoster vaccine. MMWR. 2014;63(33):729-731.

64. LexiComp Online. Available at http://online.lexi.com. Last accessed February 7, 2019.

65. GlaxoSmithKline. Highlights of Prescribing Information: Hiberix (Haemophilus b Conjugate Vaccine [Tetanus Toxoid Conjugate]). Available at https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Hiberix/pdf/HIBERIX.PDF. Last accessed February 7, 2019.

66. Centers for Disease Control and Prevention. Rotavirus Vaccine Safety. Available at https://www.cdc.gov/vaccinesafety/vaccines/rotavirus-vaccine.html. Last accessed February 7, 2019.

67. Sanofi Pasteur. Daptacel. Available at https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101572.htm. Last accessed February 7, 2019.

68. Geier DA, Geier MR. An evaluation of serious neurological disorders following immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines. Brain Dev. 2004;26(5):296-300.

69. Sanofi Pasteur. Highlights of Prescribing Information: Daptacel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed). Available at https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm103037.pdf. Last accessed February 7, 2019.

70. U.S. Food and Drug Administration. Infanrix. Available at https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm101568.htm. Last accessed February 7, 2019.

71. GlaxoSmithKline. Highlights of Prescribing Information: Boostrix (Tetanus Toxoid, Reduced Diptheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed). Available at https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Boostrix/pdf/BOOSTRIX.PDF. Last accessed February 7, 2019.

72. Sanofi Pasteur. Highlights of Prescribing Information: Adacel (Tetanus Toxoid, Reduced Diptheria Toxoid, and Acellular Pertuss is Vaccine Adsorbed). Available at https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm142764.pdf. Last accessed February 7, 2019.

73. U.S. Food and Drug Administration. Highlights of Prescribing Information: Menactra Meningococcal [groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine. Available at https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm131170.pdf. Last accessed February 7, 2019.

74. Wyeth Pharmaceuticals, Inc. Highlights of Prescribing Information: Prevnar 13 (Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]). Available at http://labeling.pfizer.com/showlabeling.aspx?id=501. Last accessed February 7, 2019.

75. Sanofi Pasteur. Haemophilus B Conjugate Vaccine (Tetanus Toxoid Conjugate) ActHIB. Available at https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm109841.pdf. Last accessed February 7, 2019.

76. Merck. Highlights of Prescribing Information: Pneumovax 23 (Pneumococcal Vaccine Polyvalent). Available at https://www.merck.com/product/usa/pi_circulars/p/pneumovax_23/pneumovax_pi.pdf. Last accessed February 7, 2019.

77. Centers for Disease Control and Prevention. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR. 2010;59(34):1102-1106.

78. Jain A, Marshall J, Buikema A, Bancroft T, Kelly JP, Newschaffer CJ. Autism occurrence by MMR vaccine status among U.S. children with older siblings with and without autism. JAMA. 2015;313(15):1534-1540.

79. Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014—United States. MMWR. 2015;63(29);620-624.

80. U.S. Department of Health and Human Services. Vaccine Adverse Event Reporting System (VAERS). Available at https://vaers.hhs.gov. Last accessed February 7, 2019.

81. Centers for Disease Control and Prevention. Vaccine Safety Datalink (VSD) Project. Available at https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/index.html. Last accessed February 7, 2019.

82. Centers for Disease Control and Prevention. Clinical Immunization Safety Assessment (CISA) Project. Available at https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html. Last accessed February 7, 2019.

83. Immunization Safety Review Committee. Immunization Safety Review: Vaccines and Autism. Washington, DC: National Academies Press; 2004.

84. Gerber JS, Offit PA. Vaccines and autism: a tale of shifting hypotheses. Clin Infect Dis. 2009;48(4):456-461.

85. Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics. 2006;118(1):e139-e150.

86. Hornig M, Briese T, Buie T, et al. Lack of association between measles virus vaccine and autism with enteropathy: a case-control study. PLoS One. 2008;3(9):e3140.

87. D'Souza Y, Fombonne E, Ward BJ. No evidence of persisting measles virus in peripheral blood mononuclear cells from children with autism spectrum disorder. Pediatrics. 2006;118(4):1664-1675.

88. Schechter R, Grether JK. Continuing increases in autism reported to California's developmental services system: mercury in retrograde. Arch Gen Psychiatry. 2008;65(1):19-24.

89. U.S. Food and Drug Administration. Thimerosal in Vaccines: Questions and Answers. Available at https://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm070430.htm. Last accessed February 7, 2019.

90. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23-33.

91. U.S. Food and Drug Administration. Update on Rotavirus Vaccine. Available at https://wayback.archive-it.org/7993/20170404184054/https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm205539.htm. Last accessed February 7, 2019.

92. Hua W, Izurieta HS, Slade B, et al. Kawasaki disease after vaccination: reports to the Vaccine Adverse Event Reporting System, 1990–2007. Pediatr Infect Dis J. 2009;2(11):943-947.

93. Centers for Disease Control and Prevention. Guillain-Barré Syndrome and Flu Vaccine. Available at https://www.cdc.gov/flu/protect/vaccine/guillainbarre.htm. Last accessed February 7, 2019.

94. Centers for Disease Control and Prevention. Guillain-Barré Syndrome and Menactra Meningococcal Vaccine. Available at https://www.cdc.gov/vaccinesafety/concerns/history/gbs-menactra-faqs.html. Last accessed February 7, 2019.

95. Centers for Disease Control and Prevention. Measles Cases and Outbreaks. Available at https://www.cdc.gov/measles/cases-outbreaks.html. Last accessed February 7, 2019.

96. Joyner C. Parents Homeschool to Avoid Vaccinating Their Kids. Available at http://usatoday30.usatoday.com/news/health/2008-10-21-home-school-vaccinate_N.htm. Last accessed February 7, 2019.

97. Gust DA, Darling N, Kennedy A, Schwartz B. Parents with doubts about vaccines: which vaccines and reasons why. Pediatrics. 2008;122(4):718-725.

98. Meyerhoff AS, Jacobs RJ. Do too many shots due lead to missed vaccination opportunities? Does it matter? Prev Med. 2005;41(2):540-544.

99. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2015.

100. Kroger AT, Duchin J, Vázquez M. General Best Practice Guidelines for Immunization. Available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html. Last accessed February 7, 2019.

101. Centers for Disease Control and Prevention. VFC Detailed Questions and Answers for Parents. Available at https://www.cdc.gov/vaccines/programs/vfc/parents/qa-detailed.html. Last accessed February 7, 2019.

102. National Vaccine Advisory Committee. Standards for child and adolescent immunization practices. Pediatrics. 2003;112(4):958-963.

103. Adetunji Y, Macklin D, Patel R, Kinsinger L. American College of Preventive Medicine practice policy statement: childhood immunizations. Am J Prev Med. 2003;25(2) 169-175.

104. Lieu TA, Capra AM, Makol J, Black SB, Shinefield HR. Effectiveness and cost-effectiveness of letters, automated telephone messages or both for underimmunized children in a health maintenance organization. Pediatrics. 1998;101(4):E3.

105. Irigoyen MM, Findley S, Earle B, Stambaugh K, Vaughan R. Impact of appointment reminders on vaccination coverage at an urban clinic. Pediatrics. 2000;106(4):919-923.

106. Dini EF, Linkins RW, Sigafoos J. The impact of computer-generated messages on childhood immunization coverage. Am J Prev Med. 2000;18(2):132-139.

107. U.S. Food and Drug Administration. Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine. Available at https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm365647.htm. Last accessed February 7, 2019.

108. Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR. 2015;64(11):300-304.

109. Lu PJ, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States,uptake of the first new vaccine to target seniors. Vaccine. 2009;27(6):882-887.

110. Poland GA, Shefer AM, McCauley M, et al. Standards for adult immunization practices. Am J Prev Med. 2003;25(2):144-150.

111. Lu PJ, Euler GL, Harpaz R. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med. 2011;40(2):e1-e6.

112. Willis BC, Ndiaye SM, Hopkins DP, Shefer A. Improving influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among adults aged <65 years at high risk: a report on recommendations of the Task Force on Community Preventive Services. MMWR. 2005;54(RR5):1-11.

113. U.S. Food and Drug Administration. FDA Approves Expanded Use of Gardasil 9 to Include Individuals 27 through 45 Years Old. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622715.htm. Last accessed February 7, 2019.

114. Centers for Disease Control and Prevention. HPV Vaccination Coverage Data. Available at https://www.cdc.gov/hpv/hcp/ vacc-coverage/index.html. Last accessed February 6, 2019.

115. Hviid A, Hansen JV, Frisch M, Melbye M. Measles, mumps, rubella vaccination and autism: a nationwide cohort study. Ann Intern Med. 2019; [Epub ahead of print].

Evidence-Based Practice Recommendations Citations

1. Advisory Committee on Immunization Practices. Recommended immunization schedules for persons aged 18 years and younger—United States, 2019. MMWR. 2019;68(5):112-114. Available at https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. Last accessed February 15, 2019.

2. Advisory Committee on Immunization Practices. Recommended immunization schedule for adults aged 19 years and older—United States, 2019. MMWR. 2019;68(5):115-118. Available at https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf. Last accessed February 15, 2019.


Copyright © 2019 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.